An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Reply to correspondence on "Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study"
Reply to correspondence on "Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study"
Eileen Laurel Yoon et al.
Clin Mol Hepatol.2024 Oct.
Fujii H, Iwaki M, Kamada Y. Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”. Clin Mol Hepatol. 2024;30:281–283.
-
PMC
-
PubMed
Oh JH, Jun DW. Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences. Clin Mol Hepatol. 2024;30:168–170.
-
PMC
-
PubMed
Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study. Clin Mol Hepatol. 2024;30:225–234.
-
PMC
-
PubMed
Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559–1569.
-
PMC
-
PubMed
Yoon EL, Jun DW. Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”. Clin Mol Hepatol. 2023;29:1050–1051.
-
PMC
-
PubMed